Business Context and Reporting Period
Anixa Biosciences, Inc. (ANIX) is a biotechnology company developing vaccines and therapies for oncology, specifically focusing on triple-negative breast cancer (TNBC), ovarian cancer, and a chimeric endocrine receptor T cell (CAR-T) therapy. The company operates as a non-accelerated filer and smaller reporting company. This summary covers the quarterly period ended July 31, 2024.
Key Financial Metrics
| Metric | Three Months Ended July 31, 2024 | Nine Months Ended July 31, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss (Attributable to Common Shareholders) | $(3,277,000) | $(9,671,000) |
| Net Loss Per Share (Basic & Diluted) | $(0.10) | $(0.30) |
| Operating Expenses | $3,592,000 | $10,668,000 |
| Research & Development Expenses | $1,925,000 | $4,920,000 |
| General & Administrative Expenses | $1,667,000 | $5,748,000 |
| Interest Income | $277,000 | $883,000 |
| Cash and Cash Equivalents (End of Period) | $1,225,000 | $1,225,000 |
| Short-term Investments | $19,520,000 | $19,520,000 |
| Total Liquidity (Cash + Investments) | $20,745,000 | $20,745,000 |
| Total Liabilities | $2,217,000 | $2,217,000 |
Material Changes vs. Prior Period
- Revenue: The company reported no revenue for the three or nine months ended July 31, 2024. This contrasts with the nine months ended July 31, 2023, which included $210,000 in revenue from a legacy patent licensing agreement.
- Operating Expenses: Total operating expenses increased by approximately $748,000 (26%) for the three months and $2,498,000 (31%) for the nine months compared to the prior year periods. This was driven primarily by increased external R&D costs for the breast cancer vaccine and CAR-T therapeutics programs.
- Net Loss: Net loss attributable to common shareholders increased to $(3.28) million for the quarter and $(9.67) million for the nine months, compared to $(2.51) million and $(7.12) million in the respective prior year periods.
- Liquidity: Total cash, cash equivalents, and short-term investments decreased by approximately $3.1 million during the nine months ended July 31, 2024, from $23.8 million at the end of fiscal 2023 to $20.7 million.
Guidance, Outlook, and Risks
- Clinical Progress:
- Breast Cancer Vaccine: Phase 1 trials are ongoing across three segments (post-treatment, prophylactic mastectomy, and residual disease). Immunological data presented in December 2023 showed antigen-specific T cell responses. New data is expected at the SITC Annual Meeting in November 2024.
- CAR-T Therapeutics: Phase 1 trials for ovarian cancer are ongoing. Two of six patients treated to date have shown anecdotal signs of efficacy (tumor necrosis). One patient is being re-dosed following FDA approval.
- Funding and Liquidity: Management believes existing cash and investments ($20.7 million) are sufficient to fund operations for at least the next 12 months. The company raised approximately $2.98 million net of expenses during the nine months ended July 31, 2024, via an at-the-market (ATM) equity offering. Approximately $97 million remains available under the current ATM program.
- Risks: The company has no revenue from its core vaccine or therapeutic programs and does not expect to generate such revenue in the near term. Future profitability depends on licensing technologies to large pharmaceutical companies, which may take several years and depends on positive clinical trial results. The company has a history of net operating losses and a full valuation allowance against deferred tax assets.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $20.7 million liquidity position against the current quarterly burn rate of approximately $3.3 million in net loss.
- ATM Offering Capacity: Confirm the remaining $97 million capacity under the at-the-market offering and the potential for dilution if further capital is raised.
- Clinical Milestones: Monitor the upcoming November 2024 SITC presentation for breast cancer vaccine data and the re-dosing progress of the CAR-T patient.
- Stock-Based Compensation: Note that non-cash stock-based compensation was significant ($1.18 million for the quarter; $3.70 million for the nine months), impacting reported expenses.
- Noncontrolling Interest: Review the impact of the subsidiary Certainty Therapeutics, Inc., which holds a 4.4% noncontrolling interest owned by The Wistar Institute.